Comparison of tacrine-induced cytotoxicity in primary cultures of rat, mouse, monkey, dog, rabbit, and human hepatocytes

Drug and Chemical Toxicology

Volumn 19, Issue 1-2, 1996, Pages 59-70

  Monteith, D K ^a   Theiss, J C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELL ENZYME; LACTATE DEHYDROGENASE; TACRINE;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG SENSITIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CULTURE; LIVER TOXICITY; MALE; MONKEY; MONOLAYER CULTURE; MOUSE; NONHUMAN; RABBIT; RAT;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 0029936176     PISSN: 01480545     EISSN: None     Source Type: Journal    
DOI: 10.3109/01480549609002196     Document Type: Article

References (16)

1. P. B. Watkins, H. J. Zimmerman, M. Knapp, S. I. Gracon and K. W. Lewis, Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease, JAMA 271, 992 (1994)
2. P. Dogterom, J. F. Nagelkerke and G. J. Mulder, Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of glutathione and vitamin E, Biochem Pharmacol, 7, 2311 (1988).
3. R. M. Walker, D W Clarke, G. S Smith, G. E. Macallum, N. J. Barsoum and P. Greaves, Hepatotoxicity of tacrine in animal models, The Toxicologist 9, 197 (1989).
4. T. A. Smolarek, C. V. Higgins and D. E. Amacher, The biotransformation of tetrahydroaminoacridine (THA) in cultured hepatocytes as the cause for relative cytotoxicity in 3 species, The Toxicologist 10, 329 (1990).
5. D. K. Monteith and J. C. Theiss, The role of metabolism in the cytotoxicity of tetrahydroaminoacridine (THA) in hepatocytes, The Toxicologist 13, 139 (1993).
6. C. J. Viau, R. D. Curren and K. Wallace, Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes, Drug Chem. Toxicol. 16, 227 (1993).
7. S. Madden, T. F. Woolf, W. F. Pool and B. K. Park, An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro, Biochem. Pharmacol. 46, 13 (1993).
8. C. J. Maslansky and G. M. Williams, Primary cultures and the levels of cytochrome P450 in hepatocytes from mouse, rat, hamster, and rabbit liver, In Vitro 18, 683 (1982)
9. D. Acosta, D. B. Mitchell, E. M. B. Sorensen and J. V. Bruckner. The metabolism and toxiciry of xenobiotics in a primary culture system of postnatal rat hepatocytes. In: E. J. Rauckman and G. Padilla (eds) The Isolated Hepatocyte: Use in Toxicology and Xenobiotic Transformation, Academic Press, pp. 265 (1987).
10. D. K. Monteith and S. C. Strom, A comparison of the inhibition of deacetylase in primary cultures of rat and human hepatocytes effecting metabolism and binding of 2-acetylaminofluorene, Cell Biol Toxicol. 6, 269 (1990).
11. S. C. Strom, R. L. Jirtle, R. S. Jones, D. L, Novicki, M. R. Rosenberg, A. Novotny, G. Irons, J, R. McLain and G. Michalopoulos, Isolation, culture, and transplantation of human hepatocytes, JNCI 68, 771 (1982).
12. M. N. Berry and D. S. Friend, High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural analysis, J. Cell Biol. 43, 506 (1969).
13. P. O. Seglen, Preparation of isolated rat liver cells, Methods Cell Biol. 13, 29 (1976).
14. J. Deschenes, J. P. Valet and N. Marceau, Hepatocytes from newborn and weanling rats in monolayer culture: Isolation by perfusion, fibronectin-mediated adhesion, spreading and functional activities, In Vitro 16, 722 (1980).
15. T. F. Woolf, W. F. Pool, S. M. Bjorge, T. Chang, O. P, Goel, C. F. I. Purchase, M. C. Schroeder, K. L. Kunze, W F. Trager, Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations: species difference, Drug Metab. Dispos. 21, 874 (1993).
16. W McNally, M. Roth, R. Young, H. Bockbrader and T. Chang, Quantitative whole-body autoradiographic detemination of tacrine tissue distribution in rats following intravenous or oral dose, Pharmaceutical Res. 6, 924 (1989).